Spironolactone Ceva

RSS

spironolactone

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for this product has been withdrawn due to the application of the sunset clause.

This EPAR was last updated on 10/05/2021

Authorisation details

Product details
Name
Spironolactone Ceva
Agency product number
EMEA/V/C/000105
Active substance
spironolactone
International non-proprietary name (INN) or common name
spironolactone
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QC03DA01
Publication details
Marketing-authorisation holder
Ceva Santé Animale
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
20/06/2007
Contact address
10 avenue de la Ballastière
33500 Libourne
France

Product information

31/10/2012 Spironolactone Ceva - EMEA/V/C/000105 - IAIN/0014

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Diuretics

Therapeutic indication

For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.

Assessment history

How useful was this page?

Add your rating